Table 2 Information for virus injection
From: Differences in neurotropism and neurotoxicity among retrograde viral tracers
Virus | Volume (nL) | Titer (particles/mL) | Injection site | Coordinates (AP, ML, DV) |
|---|---|---|---|---|
RV-B2C-EGFP | 2000 | 4x107 | popliteal lymph node | NA |
RV-152 | 2000 | 5×109 | popliteal lymph node | NA |
PRV-∆TK-∆US9-EGFP | 200 | 1×109 | LHA | (-1.0, 1.22, 4.93) |
RV-∆G-EGFP | 100 | 4×109 | LHA | (-1.0, 1.22, 4.93) |
| Â | Â | Â | dLGN | (-2.35, 2.26, 2.7) |
RV-∆G-Cre-tagBFP | 100 | 2×109 | LHA | (-1.0, 1.22, 4.93) |
rAAV2-retro-YFP | 200 | 2×1012 | LHA | (-1.0, 1.22, 4.93) |
| Â | Â | Â | dLGN | (-2.35, 2.26, 2.7) |
rAAV2-retro-Cre-tagBFP | 50 | 8×1012 | LHA | (-1.0, 1.22, 4.93) |
| Â | Â | Â | dLGN | (-2.35, 2.26, 2.7) |
Virus co-injection: | Â | Â | LHA | (-1.0, 1.22, 4.93) |
RV-∆G-EGFP | 150 | 4×109 | dLGN | (-2.35, 2.26, 2.7) |
rAAV2-retro-Cre-tagBFP | 50 | 8×1012 | MPO | (0.15, 0.5, 4.7) |
EnvA-RV-∆G-DsRed | 250 | 3×109 | LHA | (-1.0, 1.22, 4.93) |
| Â | Â | Â | mPFC | (1.6, 0.45, 0.8-1.2) |
| Â | Â | Â | dLGN | (-2.35, 2.26, 2.7) |
rAAV9-EGFP-TVA | 300 | 6×1012 | mPFC | (1.6, 0.45, 0.8-1.2) |
| Â | Â | Â | V1 | (-3.4, 2.25, 0.6) |
rAAV9-DIO-G | 200 | 6×1012 | PVN | (-0.7, 0.25, 4.7) |